Compare Amphastar Pharmaceuticals Inc (AMPH) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Revvity Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Revvity Inc trades at $115.76 (market cap $12.94B). The key difference: Revvity Inc is far larger — about 15× Amphastar Pharmaceuticals Inc's market cap, and Revvity Inc pays a 0.24% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | RVTY | |
|---|---|---|
Market Cap | $863.95M | $12.94B |
Sector | Health | Technology |
52-Week High | $30.81 | $117.75 |
52-Week Low | $16.87 | $82.26 |
Enterprise Value | $1.26B | $15.26B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
RVTY trades at $114.66, up 0.37% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 54.98% gross margin and $241.20M net income for 2025, supported by positive news including product launches and raised 2026 guidance. Analyst consensus is a buy with a $120.50 price target, indicating potential upside from current levels.
Outlook remains positive due to consistent earnings outperformance and innovation in diagnostics, but risks include high P/E valuation and competitive pressures. Investors may find opportunity in sustained margin strength and AI integration, though macroeconomic sensitivity warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
